(redirected from Well-Differentiated Neuroendocrine)
WDNEWhich Does Not Exist (Scientology)
WDNEWell-Differentiated Neuroendocrine (carcinoma)
Copyright 1988-2018 AcronymFinder.com, All rights reserved.
References in periodicals archive ?
Within the spectrum of purer neuroendocrine tumors, the extremely rare prostatic carcinoid is now officially labeled as well-differentiated neuroendocrine tumor (carcinoid), the aggressive small cell neuroendocrine carcinoma (SCNEC) is retained, and the new group of LCNEC is added.
The majority of researchers recommend considering the more aggressive component of MANEC (19), although few studies indicate that MANEC with a well-differentiated neuroendocrine component (grade 1 or 2) should be treated as an adenocarcinoma, whereas MANECs with grade 3 NEC should be treated as an NEC (4,20).
It distinguishes adenocarcinoma with Paneth cell-like neuroendocrine differentiation as a separate entity, along with the usual adenocarcinoma with neuroendocrine differentiation, well-differentiated neuroendocrine tumor, small cell neuroendocrine carcinoma and large cell neuroendocrine carcinoma (1).
CAPTEM is one of the suggested treatment regimens for progressive well-differentiated neuroendocrine tumors.
Klimstra, "Effect of tumor heterogeneity on the assessment of Ki67 labeling index in well-differentiated neuroendocrine tumors metastatic to the liver: Implications for prognostic stratification," The American Journal of Surgical Pathology, vol.
Wolin, "Challenges in the diagnosis and management of well-differentiated neuroendocrine tumors of the lung (typical and atypical carcinoid): current status and future considerations," Oncologist, vol.
GP are composed of three cell types: (1) epithelioid cells resembling well-differentiated neuroendocrine tumors or paraganglioma in both cytologic and architectural features; (2) spindled cells resembling those seen in peripheral nerve sheath tumors; and (3) ganglion-like cells with characteristic abundant cytoplasm and prominent nucleoli (Figure 3).
Ferrero et al., "Continuous 5-fluorouracil infusion plus long acting octreotide in advanced well-differentiated neuroendocrine carcinomas.
Recent studies have shown that these tumors might actually include 2 heterogeneous subgroups with a different pathogenesis: well-differentiated neuroendocrine carcinomas (WD-NECs) characterized by mutations in MEN1, DAXX, and ATRX genes and poorly differentiated neuroendocrine carcinomas (PD-NECs) characterized by p53 and RB1 mutations probably derived from the neuroendocrine differentiation of adenocarcinomas [8,11,12].
Microscopy showed a well-differentiated neuroendocrine neoplasm (low grade) involving tip, mid part and small part of the base.
Bushnell et al., "NANETS treatment guidelines: Well-differentiated neuroendocrine tumors of the stomach and pancreas," Pancreas, vol.
Grimaldi et al., "Shortened interval of long-acting octreotide administration is effective in patients with well-differentiated neuroendocrine carcinomas in progression on standard doses," Journal of Endocrinological Investigation, vol.
Full browser ?